Literature DB >> 32745657

Astrocyte elevated gene-1 as a novel therapeutic target in malignant gliomas and its interactions with oncogenes and tumor suppressor genes.

Mahmoud Osama1, Mostafa Nasr Mostafa2, Mohammed Ali Alvi3.   

Abstract

Astrocyte elevated gene-1 (AEG-1) is an oncogene and a critical signaling molecule that has a wide variety of interactions with other oncogenes and tumor suppressor genes, leading to increasing malignant properties of malignant gliomas, such as invasion, angiogenesis, metastasis, and chemoresistance. Its overexpression is enhanced by many factors such as exposure of the cells to human immunodeficiency virus type 1 (HIV-1), HIV-1 envelop glycoprotein 120, hypoxia, or glucose deprivation. Thorough understanding of these interactions along with AEG-1 inducers and repressors is important in setting a successful treatment plan targeting this oncogene. Since its discovery in 2002, AEG-1 has made a significant impact in improving our understanding of mechanism of malignant tumors progression, such as breast carcinomas, melanoma, and malignant gliomas. Therefore, it has been a novel therapeutic target for the past two decades. Herein, we focus on the role of AEG-1 in malignant gliomas and its interaction with other signaling molecules.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AEG-1; Astrocyte elevated gene-1; Astrocytoma; Glioblastoma multiforme; MTDH; Malignant glioma.

Year:  2020        PMID: 32745657     DOI: 10.1016/j.brainres.2020.147034

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  2 in total

1.  T4 reduces cisplatin resistance by inhibiting AEG-1 gene expression in lung cancer cells.

Authors:  Tian-Jiao Song; Xiao-Hong Lin; Ping-Ting Huang; Yu-Qing Chen; Li-Min Chen
Journal:  Sci Rep       Date:  2022-07-06       Impact factor: 4.996

2.  Circular RNA: A novel type of biomarker for glioma (Review).

Authors:  Wei Sun; Huandi Zhou; Xuetao Han; Liubing Hou; Xiaoying Xue
Journal:  Mol Med Rep       Date:  2021-06-24       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.